Hemogenyx Pharmaceuticals Secures £709,200 for Phase 1 Clinical Trials

HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has shared an announcement.

Hemogenyx Pharmaceuticals has secured institutional investment of £709,200 to continue its Phase 1 clinical trials for HG-CT-1, a Chimeric Antigen Receptor T-cell therapy targeting relapsed/refractory acute myeloid leukemia in adults. This funding reflects confidence in the company’s progress and supports its mission to advance innovative treatments for aggressive diseases, with the new shares expected to be traded on the London Stock Exchange by March 18, 2025.

More about HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with its US subsidiaries located in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.

YTD Price Performance: -24.57%

Average Trading Volume: 17,430

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £11.01M

For a thorough assessment of HEMO stock, go to TipRanks’ Stock Analysis page.